Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD

NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs

Published on February 2, 2009 at 12:13 AM

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has recently submitted a grant application to the Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs. If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure (MCM) against bio-terrorism and emerging infectious diseases such as Ebola/Marburg, and Dengue.

The Company has already demonstrated that some of the nanoviricides we have created are broad-spectrum. It is believed that viruses are unlikely to escape such broad-spectrum nanoviricides by mutation because such mutations would also cause a loss of infectivity.

At present, other MCM efforts have generally resulted in highly specific one-bug-one-drug type of therapies, such as vaccines, antibodies, certain anti-sense therapeutics, and some other antivirals. Thus, a large number of drugs, vaccines and antibodies would need to be stockpiled to mitigate the threat from a countless number of pathogens and their known mutants. Further, if a virus mutates further, then most such agents are likely to become ineffective. Mutations are common in many viruses, and can also be genetically engineered to produce devastating bio-terrorism agents.

The Company has assembled a strong team comprising several renowned Institutions and Companies for the proposed project. There is no guarantee that the grant application will result in any funding.

Ebola viruses cause devastating disease with mortality rates as high as 90%. Dengue has now become endemic in most of the tropical world, and is becoming an important public health threat in the United States. A second infection from an unrelated dengue virus subtype can be life-threatening, resulting in dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). There is currently no drug or vaccine available for dengue viruses. The worldwide market for a dengue treatment could be possibly in the billions of dollars.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit